137 related articles for article (PubMed ID: 35485735)
1. Characterization of the impact of the
Abaji R; Roux V; Yssaad IR; Kalegari P; Gagné V; Gioia R; Ferbeyre G; Beauséjour C; Krajinovic M
Pharmacogenomics; 2022 May; 23(7):415-430. PubMed ID: 35485735
[No Abstract] [Full Text] [Related]
2. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Abaji R; Gagné V; Xu CJ; Spinella JF; Ceppi F; Laverdière C; Leclerc JM; Sallan SE; Neuberg D; Kutok JL; Silverman LB; Sinnett D; Krajinovic M
Oncotarget; 2017 Jul; 8(27):43752-43767. PubMed ID: 28574850
[TBL] [Abstract][Full Text] [Related]
3.
Mootoosamy C; Kondyli M; Serfaty SA; Tremblay DÉ; Gagné V; Ribère M; Laverdière C; Leclerc JM; Sinnett D; Tran TH; Krajinovic M
Pharmacogenomics; 2023 Mar; 24(4):199-206. PubMed ID: 36946317
[TBL] [Abstract][Full Text] [Related]
4. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
[TBL] [Abstract][Full Text] [Related]
5. A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
Fine BM; Kaspers GJ; Ho M; Loonen AH; Boxer LM
Cancer Res; 2005 Jan; 65(1):291-9. PubMed ID: 15665306
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Ben Tanfous M; Sharif-Askari B; Ceppi F; Laaribi H; Gagné V; Rousseau J; Labuda M; Silverman LB; Sallan SE; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Clin Cancer Res; 2015 Jan; 21(2):329-34. PubMed ID: 24907114
[TBL] [Abstract][Full Text] [Related]
7. L-asparaginase: a promising chemotherapeutic agent.
Verma N; Kumar K; Kaur G; Anand S
Crit Rev Biotechnol; 2007; 27(1):45-62. PubMed ID: 17364689
[TBL] [Abstract][Full Text] [Related]
8. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
9. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
[TBL] [Abstract][Full Text] [Related]
10. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
Ronghe M; Burke GA; Lowis SP; Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
[TBL] [Abstract][Full Text] [Related]
11. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
[TBL] [Abstract][Full Text] [Related]
12. Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Chen SH
Pediatr Neonatol; 2015 Oct; 56(5):287-93. PubMed ID: 25603726
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
14. MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis.
Akaogi K; Ono W; Hayashi Y; Kishimoto H; Yanagisawa J
BMC Cancer; 2013 Feb; 13():65. PubMed ID: 23388179
[TBL] [Abstract][Full Text] [Related]
15. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL.
Stams WA; den Boer ML; Beverloo HB; Meijerink JP; Stigter RL; van Wering ER; Janka-Schaub GE; Slater R; Pieters R
Blood; 2003 Apr; 101(7):2743-7. PubMed ID: 12433682
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Kang SM; Rosales JL; Meier-Stephenson V; Kim S; Lee KY; Narendran A
Oncogene; 2017 Oct; 36(42):5910-5913. PubMed ID: 28650467
[TBL] [Abstract][Full Text] [Related]
18. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
Douer D
Best Pract Res Clin Haematol; 2008 Dec; 21(4):647-58. PubMed ID: 19041604
[TBL] [Abstract][Full Text] [Related]
19. Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
Youssef YH; Makkeyah SM; Soliman AF; Meky NH
Cancer Chemother Pharmacol; 2021 Aug; 88(2):313-321. PubMed ID: 33959786
[TBL] [Abstract][Full Text] [Related]
20. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
